AAPS PharmSci 360 2026
Information
Visit Gattefossé at AAPS PharmSci 360 and discover new ways to expand your formulation toolbox.
Learn how our solutions enable both small and large molecule delivery across a wide range of oral, topical, and transmucosal dosage forms. Discover technologies for improved solubility, permeation enhancement, lymphatic uptake, and food effect mitigation.
Enhancing Your Journey from Concept to Commercialization
Visit our team at Booth #1318 to learn how we overcome drug delivery challenges for the most challenging molecules in your pipeline.
Tailored Project Guidance
Deep lipid expertise at our US Technical Center of Excellence, enabling delivery of:
PROTACs
Peptides
Emerging Beyond-Rule-of-5 Compounds
Oral Bioavailability Enhancement
Improve Solubility
Enhance Permeability
Increase Absorption
Mitigate Food Effect
Topical & Transdermal Innovation
Solubilizers
Penetration Enhancers
Emulsifiers & Emollients
Viscosity Enhancers
Advancing Lipid-Based Formulation Development
(T1030-09-52) Development and Optimization of a Patient-Friendly Lidocaine Nanoemulgel for Enhanced Skin Permeation
Tuesday, October 27, 2026 | 10:30 AM - 11:30 AM CT
Vaibhavi Bhoyarekar, MS
Application Laboratory Scientist I
This study presents the successful development of a novel lidocaine nanoemulgel that leverages the solubilizing and permeation-enhancing properties of Labrasol® ALF, Capryol® 90, and Transcutol® P to achieve superior topical delivery. By carefully balancing lipid excipients with a hydrogel base, researchers created a stable formulation that combines easy application with the enhanced skin penetration of a nanoemulsion. Remarkably, this optimized 3% lidocaine formulation delivered a more sustained, efficient drug release over 72 hours than a marketed 5% lidocaine gel (Topicaine®), showcasing the impact of advanced excipient selection on topical drug performance.
(M1330-09-48) Tablet Lipid-Based Drug Delivery Through Adsorption Process: Development and Use of a Stepwise Methodology
Monday, October 26, 2026 | 1:30 PM - 2:30 PM CT
Claudia Gama, Pharm.D.
Technical Support - Pharmaceuticals
This study outlines a strategic decision tree for transforming liquid lipid-based formulations into robust oral solid dosage forms, utilizing Labrasol® ALF and Labrafac™ MC60 to tackle the bioavailability challenges of BCS Class II/IV APIs like ticagrelor. By applying a modified SeDeM-SLA expert system, researchers evaluated the flow, compressibility, and biorelevant dissolution of these lipid excipients when adsorbed onto various inert carriers. The methodology successfully pinpointed the optimal carrier to maximize drug release and enable direct compression tableting, providing formulators with a clear, data-driven roadmap for advancing lipid-based suspensions into final solid dosage forms.
(M1330-01-02) TIM-1 as a Biorelevant Dynamic In Vitro Tool to Screen Lipid-Based Formulations
Monday, October 26, 2026 | 1:30 PM - 2:30 PM CT
Arnaud Bourderi, MS
PhD Student
This study demonstrates the value of the TIM-1 dynamic gastrointestinal model in screening lipid-based formulations (LBFs) to improve the oral bioavailability of challenging BCS Class IV drugs like ticagrelor. By evaluating formulations powered by Labrasol® ALF, Labrafac™ MC60, Maisine® CC, and Transcutol® HP, researchers proved that tailored LBFs deliver a significantly higher bioaccessible fraction than the pure active pharmaceutical ingredient. Crucially, the dynamic TIM-1 data revealed that maximum intestinal solubilization does not automatically translate to optimal absorption, emphasizing the critical importance of strategic lipid excipient selection in overcoming complex oral delivery hurdles.